Clinically significant ascites, defined as ascites that is symptomatic or has resulted in a paracentesis in the past 3 monthsXx_NEWLINE_xXAscites or pleural effusion requiring intervention or that required intervention or recurred within three months prior to randomizationXx_NEWLINE_xXPericardial effusion (except trace effusion identified by echocardiogram) within three months prior to randomizationXx_NEWLINE_xXNo history of the following:\r\n* Class III or IV congestive heart failure (CHF)\r\n* Grade 3 or 4 thromboembolic event =< 6 months\r\n* Pericardial effusion =< 12 months (any grade)\r\n* Pericardial involvement with tumor\r\n* Grade 2 or higher pleural effusion =< 6 monthsXx_NEWLINE_xXPatients with malignant pleural effusions that do not resolve after first-line systemic therapy. Patients with pleural effusions that have become too small for thoracentesis at the time of registration would be permitted on study, indicating a significant response to first-line systemic therapy.Xx_NEWLINE_xXPatients must not have active pericardial effusion, ascites or pleural effusion of any grade based on chest x-ray and echocardiogram within 28 days prior to registration; exception: if the effusion is suspected to be related to the leukemia, the patient may have pericardial effusion =< grade 2 or pleural effusion =< grade 1Xx_NEWLINE_xXPatient has pleural effusion, ascites, or pericardial fluid requiring drainage Note: Patient who had drain removal ? 14 days prior to planned first dose of study drug and has no sign of worsening is eligibleXx_NEWLINE_xXUncontrolled ascites requiring weekly large-volume paracentesis for 2 consecutive weeks prior to initiation of study treatmentXx_NEWLINE_xXHave symptomatic ascites or pleural effusion.Xx_NEWLINE_xXHas extensive pleural effusion which occupies greater than 50% of the total lung volume observed on screening imagingXx_NEWLINE_xXSymptomatic ascites or pleural effusion.Xx_NEWLINE_xXUncontrolled pleural effusion, pericardial effusion, or ascitesXx_NEWLINE_xXEvidence of fluid retention at Screening (including, for example, peripheral edema, pleural effusion, or ascites on physical or radiological examination) or history of severe capillary leak syndromeXx_NEWLINE_xXSymptomatic ascites or pleural effusionXx_NEWLINE_xXHas symptomatic ascites or pleural effusion. A participant who is clinically stable following treatment for these conditions (including therapeutic thoraco- or paracentesis) is eligible.Xx_NEWLINE_xXPleural effusion or ascites that causes respiratory compromise (>= NCI-CTCAE version 4.0 grade 2 dyspnea)Xx_NEWLINE_xXParticipants (all indications) with confirmed bilateral pleural effusion and NSCLC participants with confirmed uni- or bilateral pleural effusion by X-ray are not eligibleXx_NEWLINE_xXRefractory encephalopathy or ascitesXx_NEWLINE_xXHas ascites or pleural effusion by physical examXx_NEWLINE_xXUncontrolled symptomatic ascites or pleural effusions within 6 months.Xx_NEWLINE_xXPatients with significant visceral fluid collections including ascites, pericardial effusions, pleural effusions or others may experience delayed clearance of methotrexate and inability tolerate the proposed study treatment; while these are not absolute exclusions the Study Chair or co-Chairs should be contacted to discuss possible enrollment; patients with significant ascites defined as European Association for the Study of the Liver >= grade 2, or with asymptomatic pleural effusions with an estimated size > 200 mL, or with symptomatic pleural effusion of any size will be excludedXx_NEWLINE_xXSubjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior cycle 1, day 1Xx_NEWLINE_xXPatients with active extra-abdominal disease including active malignant pleural effusion; patients who have been successfully treated with neoadjuvant chemotherapy and no longer have (malignant) pleural effusions may be includedXx_NEWLINE_xXSubjects with pleural effusions requiring thoracentesis or ascites requiring paracentesisXx_NEWLINE_xXFluctuating ascitesXx_NEWLINE_xXHas symptomatic ascites or pleural effusion.Xx_NEWLINE_xXUncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage more than once every 28 daysXx_NEWLINE_xXNo clinically significant pleural effusionXx_NEWLINE_xXClinical evidence of ascites (trace ascites on imaging acceptable)Xx_NEWLINE_xXCirrhosis at a level of Child-Pugh B (or worse) or cirrhosis (any degree) and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis (i.e. ascites from cirrhosis requiring diuretics or paracentesis)Xx_NEWLINE_xXNo evidence of clinically apparent ascites or active encephalopathy, and/or varices that have not been treated; subjects with controlled ascites or encephalopathy are eligible so long as they meet Childs-Pugh score criterion; please note that controlled ascites and encephalopathy require scores of 2 each when calculating the C-P scoreXx_NEWLINE_xXParticipants with confirmed bilateral pleural effusionXx_NEWLINE_xXPresence of fluid collection (ascites, pleural, or pericardial effusion) that interferes with methotrexate clearance or makes methotrexate use contraindicated.Xx_NEWLINE_xXPatients with non-malignant pleural effusion are eligible\r\n* If a pleural effusion is present, the following criteria must be met to exclude malignant involvement:\r\n** When pleural fluid is visible on both the CT scan and on a chest x-ray, a pleuracentesis is required to confirm that the pleural fluid is cytologically negative\r\n** Exudative pleural effusions are excluded, regardless of cytology\r\n** Effusions that are minimal (i.e, not visible on chest x-ray) that are too small to safely tap are eligibleXx_NEWLINE_xXPatients with clinically significant ascites or pleural effusions.Xx_NEWLINE_xXRelapsed or refractory, histologically confirmed follicular lymphoma, grade I, II, or IIIa which requires therapy defined by at least one of the following:\r\n* Constitutional symptoms \r\n* Cytopenias\r\n* High tumor burden (single mass > 7 cm, three masses > 3 cm, symptomatic splenomegaly, organ compression or compromise, ascites, pleural effusion)Xx_NEWLINE_xXPleural or pericardial effusions of any grade at study entry; subjects previously diagnosed with pleural/pericardial effusion of any grade resolved at the time of study entry are allowedXx_NEWLINE_xXUncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage proceduresXx_NEWLINE_xXClinical ascites or metastatic pleural fluidXx_NEWLINE_xXAscites refractory to medical therapy (mild to moderate ascites is allowed)Xx_NEWLINE_xXEvident symptomatic pulmonary fibrosis or interstitial pneumonitis, pleural or cardiac effusion rapidly increasing and/or necessitating prompt local treatment within seven days.Xx_NEWLINE_xXNo clinical evident ascites that required therapeutic paracentesisXx_NEWLINE_xXPleural effusion or ascites that causes respiratory compromise, grade 2 dyspneaXx_NEWLINE_xXPleural effusion or ascites that causes respiratory compromise (>= NCI-CTCAE version 4.0 grade 2 dyspnea)Xx_NEWLINE_xXPleural effusion or ascites that causes respiratory compromise (>= NCI-CTCAE version 4.0 grade 2 dyspnea)Xx_NEWLINE_xXFor NSCLC, patients with clinical stage IIB-IV patients (American Joint Committee on Cancer [AJCC], 7th edition [ed.]) are eligible, and for SCLC, limited-stage patients are eligible, if documented to be a candidate for definitive radiation and concurrent chemotherapy in the radiation oncologist or medical oncologist clinic note\r\n* Stage IV NSCLC patients are eligible only if they have a solitary brain metastasis\r\n* Patients with non-malignant pleural effusion are eligible,\r\n** If a pleural effusion is present, the following criteria must be met to exclude malignant involvement:\r\n*** When pleural fluid is visible on both the computed tomography (CT) scan and on a chest x-ray, a pleuracentesis is required to confirm that the pleural fluid is cytologically negative\r\n*** Exudative pleural effusions are excluded, regardless of cytology\r\n*** Effusions that are minimal (i.e., not visible on chest x-ray) that are too small to safely tap are eligibleXx_NEWLINE_xXGreater than minimal, exudative, or cytologically positive pleural effusionsXx_NEWLINE_xXEvidence of measurable disease (per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1]) outside of the peritoneal cavity (ex: mediastinal lymphadenopathy, parenchymal liver metastasis, or symptomatic pleural effusion proven or suspected to be due to cancer)\r\n* Note: Asymptomatic pleural effusion with or without minimal pleural involvement as long as there is no measurable disease outside the peritoneum/retroperitoneum is allowedXx_NEWLINE_xXParticipants with bilateral pleural effusion and NSCLC participants with uni- or bilateral effusion confirmed at screening by X-ray are not eligibleXx_NEWLINE_xXMalignant ascites that is clinically detectable by physical examination or is symptomatic; evidence of radiographic ascites that is not clinically significant will not be an exclusion criterionXx_NEWLINE_xXPleural or pericardial effusion\r\n* A patient with pleural effusion may be enrolled the effusion is sampled by thoracentesis and cytology is negative or the effusion is seen on axial imaging but not on chest x-ray and deemed too small to tap under CT or ultrasound guidanceXx_NEWLINE_xXPleural or pericardial effusion\r\n *Pleural effusions allowed if one of the following conditions are met: 1) negative cytology after adequate sampling by thoracentesis 2) effusion seen on CT scan but not on chest x-ray and deemed too small to tap under CT or ultrasound guidanceXx_NEWLINE_xXCOHORT B, GROUP 6: HEPATOCELLULAR CARCINOMA: Ascites that is not medically controlled or that required a therapeutic paracentesis within last 3 monthsXx_NEWLINE_xXPatients with pleural effusion or abdominal/peritoneal ascites, except the finding of physiological levels of fluid.Xx_NEWLINE_xXConcurrent medical condition that would increase drug toxicity: pleural or pericardial effusion, coagulation or platelet function disorder, ongoing or recent (less than 3 months gastrointestinal bleeding)Xx_NEWLINE_xXPresence of medically significant third space fluid (symptomatic pericardial effusion, ascites or pleural effusion requiring repetitive paracentesis)Xx_NEWLINE_xXPleural effusion as the only evidence of metastatic diseaseXx_NEWLINE_xXPresence of a significant pleural effusion by chest x-rayXx_NEWLINE_xXCurrent, or history of a pericardial effusion, and/or hemodynamic compromise due to pericardial effusion of any size; minimal pericardial effusion < 50 cc is not excludedXx_NEWLINE_xXClinically apparent ascites on physical examination, ascites present on imaging studies is allowedXx_NEWLINE_xXUncontrolled tumor-related pain; pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures; or, hypercalcemia or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab.Xx_NEWLINE_xXUncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage more than once every 28 daysXx_NEWLINE_xXUncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently) (patients with indwelling catheters such as PleurX® are allowed)Xx_NEWLINE_xXUncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)Xx_NEWLINE_xXThe presence of lung, liver, or known brain metastases, malignant pleural effusions, or malignant ascitesXx_NEWLINE_xXA pleural effusion of moderate severity or worse.Xx_NEWLINE_xXSymptomatic ascites or pleural effusion.Xx_NEWLINE_xXModerate or severe ascitesXx_NEWLINE_xXAscites, pleural effusion, or pericardial fluid requiring drainage in the last 4 weeks prior to registrationXx_NEWLINE_xXHas clinically relevant ascites at baseline (defined as requiring paracentesis) or with moderate radiographic ascites; a minimal amount of radiographic ascites is allowedXx_NEWLINE_xXPatients with documented significant pleural or pericardial effusions unless they are thought to be secondary to their leukemia.Xx_NEWLINE_xXGrade 2 or higher ascites, pleural, or pericardial effusion within 4 weeks of study enrollment or any history of recurrent grade 2 or higher effusions requiring ongoing drainage.Xx_NEWLINE_xXNo clinically significant pleural effusionXx_NEWLINE_xXSubjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 21 days prior to registrationXx_NEWLINE_xXParticipants with uncontrolled gross ascites or encephalopathy; assessment of ascites will be determined by the treating physicianXx_NEWLINE_xXSymptomatic pleural effusions or ascites (requiring constant or intermittent drainage)Xx_NEWLINE_xXClinically significant and/or rapidly accumulating ascites, pericardial and/or pleural effusions; mild ascites that does not preclude safe tumor biopsy as protocol specified is allowed at the discretion of the treating physicianXx_NEWLINE_xXPatients with any clinically apparent ascites or who have undergone a paracentesis within 7 days of enrollmentXx_NEWLINE_xXAscites or pericardial effusion that required intervention within 3 months prior to study treatmentXx_NEWLINE_xXPleural effusions or ascites.Xx_NEWLINE_xXUncontrolled pleural or pericardial effusion or ascites that would require recurrent drainageXx_NEWLINE_xXPatients with documented significant pleural or pericardial effusions unless they are thought to be secondary to their leukemia.Xx_NEWLINE_xXUncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)\r\n* Subjects with indwelling drainage catheters are allowedXx_NEWLINE_xXPleural effusion: when pleural fluid is visible on both CT scan and on a chest x-ray, a pleuracentesis is required to confirm that the pleural fluid is cytologically negative; patients with effusions that are minimal (i.e. not visible on chest x-ray) or that are too small to safely tap are eligibleXx_NEWLINE_xXPleural effusion or ascites that causes respiratory compromise (>= NCI-CTCAE version 4.0 grade 2 dyspnea)Xx_NEWLINE_xXPatients with PDA metastases deemed likely to limit the patient’s ability to participate in the study for the complete duration (ie. > 3 months), including but not limited to:\r\n* Presence of central nervous system (CNS) metastasis including brain metastasis or compromise resulting from extrinsic disease in the bone or dura\r\n* Presence of more than 5 liver metastases or one liver metastasis measuring more than 3 cm\r\n* Cancer antigen (CA)19-9 > 3000 U/mL\r\n* Oxygen requirement attributable to pleural effusion or other malignant process\r\n* Symptomatic ascites or radiographic evidence of more than trace ascitesXx_NEWLINE_xXA pleural effusion of moderate severity or worse.Xx_NEWLINE_xXHigh volume peritoneal or pleural effusions requiring a tap more frequently than every 14 days; moderate to severe ascitesXx_NEWLINE_xXNo clinically significant pleural effusion, baseline oxygen saturation > 92% on room airXx_NEWLINE_xXPleural effusion or ascites that causes respiratory compromise (>= NCI-CTCAE version 4.0 grade 2 dyspnea)Xx_NEWLINE_xXNo clinically significant pleural effusionXx_NEWLINE_xXClinically significant ascites defined as requiring ? 1 paracentesis every 2- weeksXx_NEWLINE_xXClinical ascitesXx_NEWLINE_xXPatients with malignant small bowel obstruction within the last 6 months, on parenteral nutrition, clinically significant ascites (palpable on physical exam and/or causing symptoms) or ascites requiring fluid removal more than twice in the last 6 weeksXx_NEWLINE_xXPatients must have a histologic diagnosis of malignant pleural mesotheliomaXx_NEWLINE_xXMarked pleural effusion or ascites above Grade 2, based on NCI-CTCAE v4.03 criteriaXx_NEWLINE_xXNo pleural or peritoneal serous effusion.Xx_NEWLINE_xXDASATINIB\r\n* Any history of second or third degree heart block (may be eligible if the subject currently has a pacemaker)\r\n* Known pulmonary arterial hypertension\r\n* Patients may not have clinically significant pleural or pericardial effusion per provider discretionXx_NEWLINE_xXNo pleural or pericardial effusion of any gradeXx_NEWLINE_xXSubjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to initiation of ABC294640Xx_NEWLINE_xXAscites requiring active medical management including paracentesisXx_NEWLINE_xXThe patient does not have cirrhosis at a level of Child-Pugh B (or worse) or cirrhosis (any degree) and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis; clinically meaningful ascites is defined as ascites from cirrhosis requiring diuretics or paracentesisXx_NEWLINE_xXModerate to large volume ascites.Xx_NEWLINE_xXPresence of third space fluid which cannot be controlled by drainage; for patients who develop or have baseline clinically significant pleural or peritoneal effusions (on the basis of symptoms or clinical examination) before or during initiation of pemetrexed therapy, consideration should be given to draining the effusion prior to dosing; however, if, in the investigator's opinion, the effusion represents progression of disease, the patient should be discontinued from study therapyXx_NEWLINE_xXContraindication to any of the required concomitant drugs or supportive treatments or intolerance to hydration due to preexisting pulmonary or cardiac impairment including pleural effusion requiring thoracentesis or ascites requiring paracentesis not due to lymphomaXx_NEWLINE_xXUncontrolled effusion e.g., presence of third space fluid that, in the opinion of the investigator, cannot be successfully controlled by drainage\r\n* Note: Patients with small effusions remaining after pleurodesis are eligible; determination of eligibility based on pleural size will be determined by the principal investigatorXx_NEWLINE_xXSignificant ascites that require therapeutic paracentesisXx_NEWLINE_xXREGORAFENIB EXCLUSION CRITERIA: Pleural effusion or ascites causing respiratory compromise (dyspnea grade 2 or higher)Xx_NEWLINE_xXPresence of ascites (as determined by clinician)Xx_NEWLINE_xXPresence of pleural effusionXx_NEWLINE_xXThe patient does not have: \r\n* Cirrhosis at a level of Child-Pugh B (or worse) or\r\n* Cirrhosis (any degree) and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis; clinically meaningful ascites is defined as ascites from cirrhosis requiring diuretics or paracentesisXx_NEWLINE_xXHistory of any other significant medical disease such as major gastric or small bowel surgery, recent drainage of significant volumes of ascites or pleural effusion (as per Investigator's judgement) or a psychiatric condition that might impair the subject's well-being or preclude full participation in the trialXx_NEWLINE_xXAny clinical or radiological ascites or pleural effusionsXx_NEWLINE_xXPleural effusion or ascites that causes respiratory compromise (? NCI-CTCAE version 4.03 Grade 2 dyspnea)Xx_NEWLINE_xXPatients with symptomatic ascites or pleural effusion; a patient who is clinically stable following treatment for these conditions is eligibleXx_NEWLINE_xXBaseline oxygen saturation > 92% on room air and no clinically significant pleural effusionXx_NEWLINE_xXPatients with evidence of a malignant pleural or pericardial effusionXx_NEWLINE_xXPatients with large and recurrent pleural or peritoneal effusions requiring frequent drainage (e.g. weekly); patients with any amount of clinically significant pericardial effusionXx_NEWLINE_xXPleural effusion or ascites that causes respiratory compromise (ie, >= grade 2 dyspnea)Xx_NEWLINE_xXContraindication to any of the required concomitant drugs or supportive treatments or intolerance to hydration due to preexisting pulmonary or cardiac impairment including pleural effusion requiring thoracentesis or ascites requiring paracentesis unless due to lymphomaXx_NEWLINE_xXUncontrolled pleural or pericardial effusion or ascites that would require recurrent drainageXx_NEWLINE_xXSubjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to enrollmentXx_NEWLINE_xXIf a pleural effusion is present and visible on both CT scan AND chest x-ray, the investigator should exclude malignant disease by pleurocentesis to confirm cytologically-negative pleural fluid; if fluid is exudative or cytologically positive for tumor cells, patient is excluded\r\n* Patients with effusions that are minimal (i.e. not visible on chest x-ray) and that are too small to safely tap are eligibleXx_NEWLINE_xXIf the patient has received pre-operative neoadjuvant chemotherapy, evidence of response must be documented by at least one of the following: decline in serum carcinoma antigen (CA)125 level, at least a 30% decrease in the sum of the longest diameter of target lesions on radiographic imaging, or resolution of ascites or pleural effusion(s)Xx_NEWLINE_xXSymptomatic ascites or pleural effusionXx_NEWLINE_xXAscites refractory to medical therapyXx_NEWLINE_xXSubjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to enrollmentXx_NEWLINE_xXAscites refractory to medical therapyXx_NEWLINE_xXPatients with large and recurrent pleural or peritoneal effusions requiring frequent drainage (e.g. weekly)Xx_NEWLINE_xXPleural/pericardial effusion or ascites > 1 LXx_NEWLINE_xXSubjects with malignant pleural effusions and malignant ascitesXx_NEWLINE_xXPatients with clinically significant pleural or pericardial effusionsXx_NEWLINE_xXAny evidence of ascites (beyond trace)Xx_NEWLINE_xXDasatinib \r\n* Known pulmonary arterial hypertension\r\n* Patients may not have pleural or pericardial effusion of any grade\r\n* Patients may not have clinically significant pleural or pericardial effusion per provider discretion\r\n* Uncontrolled hypertension: inability to maintain blood pressure below the limit of 140/90 mgHg\r\n* Any history of second or third degree heart block (may be eligible of the subject currently has a pacemaker)Xx_NEWLINE_xXPatients with known, clinically significant pericardial or pleural effusionXx_NEWLINE_xXSubjects with significant fluid retention, including ascites or pleural effusion, may be allowed at the discretion of the Principal Investigator (PI)Xx_NEWLINE_xXPatients with documented significant pleural or pericardial effusions unless they are thought to be secondary to their leukemiaXx_NEWLINE_xXPleural effusion or ascites that causes > grade 1 dyspneaXx_NEWLINE_xXCirrhosis at a level of Child-Pugh B (or worse) or cirrhosis (any degree) with a history of hepatic encephalopathy or clinical meaningful ascites resulting from cirrhosis; clinically meaningful ascites is defined as ascites resulting from cirrhosis and requiring ongoing treatment with diuretics and/or paracentesisXx_NEWLINE_xXHistory of moderate or severe ascites, bleeding esophageal varices, hepatic encephalopathy or pleural effusions related to liver insufficiency within 6 months of screeningXx_NEWLINE_xXPresence of third space fluid that cannot be controlled by drainage\r\n* For patients who develop or have baseline clinically significant pleural effusions before or during initiation of pemetrexed therapy; consideration should be given to drain the effusion prior to chemotherapy administrationXx_NEWLINE_xXMeasurable disease as per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 criteria or non-measurable disease with symptomatic malignant pleural effusion or malignant ascites; if only site of disease is a pleural effusion, cytologic confirmation of recurrence should be obtainedXx_NEWLINE_xXRecent history (within 6 months) of uncontrolled symptomatic ascites or pleural effusions.Xx_NEWLINE_xXUncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainageXx_NEWLINE_xXPatients with current cirrhotic status of Child-Pugh class A only (5-6 points with total bilirubin < 2 mg/dL for dose-escalation) with no encephalopathy and no clinical ascites (ascites controlled by diuretics is also excluded in this study).Xx_NEWLINE_xXClinically significant pleural effusion that either required pleurocentesis or is associated with shortness of breath.Xx_NEWLINE_xXPresence of fluid collection (ascites, pleural or pericardial effusion) that interferes with methotrexate clearance or makes methotrexate use contraindicatedXx_NEWLINE_xXUncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures >/=1 time per monthXx_NEWLINE_xXEvidence of significant ascites as determined by the investigatorXx_NEWLINE_xXSubjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to randomizationXx_NEWLINE_xXPatients with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to registration are NOT eligible for participationXx_NEWLINE_xXPleural effusion or ascites that causes respiratory compromise (? CTCAE Grade 2 dyspnea).Xx_NEWLINE_xXHas symptomatic ascites or pleural effusionXx_NEWLINE_xXSymptomatic ascites or pleural effusion. A participant who is clinically stable following treatment for these conditions (including therapeutic thoraco- or paracentesis) is eligible.Xx_NEWLINE_xXPatients with large and recurrent pleural or peritoneal effusions requiring frequent drainage (e.g. weekly); patients with any amount of clinically significant pericardial effusionXx_NEWLINE_xXNormal lung function with no dyspnea at rest, pleural effusion or oxygen requirementXx_NEWLINE_xXNo clinically significant pleural effusion, baseline oxygen saturation > 92% on room airXx_NEWLINE_xXNo clinically significant pleural effusion, baseline oxygen saturation > 92% on room air.Xx_NEWLINE_xXClinically significant pleural effusionXx_NEWLINE_xXClinically significant pericardial effusion, circumferential pericardial effusion, or any effusion greater than 1.0 cm at any location around the heartXx_NEWLINE_xXHas ascites that requires frequent paracentesis or a pleural effusion that requires repeated thoracentesisXx_NEWLINE_xXPresence of ascites that is not medically controlled or that required a therapeutic paracentesis within the last 3 months prior to initiation of study therapyXx_NEWLINE_xXPleural effusions that are minimal (i.e. not visible on chest x-ray) that are too small to safely tap are eligibleXx_NEWLINE_xXExudative pleural effusion, regardless of cytologyXx_NEWLINE_xXHas significant ascites or pleural effusion requiring drainage for symptom reliefXx_NEWLINE_xXClinically detectable (by physical exam) third?space fluid collections (e.g. ascites or pleural effusion) that cannot be controlled by drainage or other procedures prior to study entryXx_NEWLINE_xXPleural effusion or ascites that causes respiratory compromise (>= NCI-CTCAE version 4.0 grade 2 dyspnea)Xx_NEWLINE_xXUncontrolled effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)Xx_NEWLINE_xXPleural effusion that cannot be controlled with appropriate interventionsXx_NEWLINE_xXPleural effusion or ascites that causes respiratory compromise (eg, >= grade 2 dyspnea)Xx_NEWLINE_xXAscites, pleural effusion or pericardial fluid requiring drainage in the last 4 weeksXx_NEWLINE_xXAscites requiring active medical management, including paracentesisXx_NEWLINE_xXPleural effusion requiring active medical managementXx_NEWLINE_xXAscites requiring active medical management including paracentesis.Xx_NEWLINE_xXCytologically positive pleural effusionXx_NEWLINE_xXSubjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to randomizationXx_NEWLINE_xXPleural effusion that cannot be controlled despite appropriate interventionsXx_NEWLINE_xXActive signs and symptoms of interstitial lung disease pleural effusion or ascites that causes respiratory compromise (>= grade 2 dyspnea)Xx_NEWLINE_xXIf a pleural effusion is present, the following criteria must be met at registration to exclude malignant involvement (incurable M1a disease):\r\n* When pleural fluid is visible on both the CT scan and on a chest x-ray, a pleuracentesis is required to confirm that the pleural fluid is cytologically negative\r\n* Effusions that are minimal (i.e. not visible under ultrasound guidance) and that are too small to safely tap are eligibleXx_NEWLINE_xXSubjects with pleural effusion requiring thoracentesis or ascites requiring paracentesis within 14 days prior to admissionXx_NEWLINE_xXPatients with symptomatic effusions (pleural, pericardial, or peritoneal) and/or those who have required a procedure for symptomatic effusions within 4 weeks of start of dasatinib are ineligibleXx_NEWLINE_xXPatients must be willing and able to undergo ascites fluid collection pre- and post-study treatment if adequate ascites is present; patients without adequate ascites may also participate in the trialXx_NEWLINE_xXPatients with pre-existing interstitial lung disease (ILD), or pericardial/pleural effusion of grade 2 or higher; trace pericardial or pleural effusion is acceptableXx_NEWLINE_xXThe presence of liver, or known brain metastases, malignant pleural effusions, or malignant ascitesXx_NEWLINE_xXPatients with large and recurrent pleural or peritoneal effusions requiring frequent drainage (e.g. weekly); patients with any amount of clinically significant pericardial effusionXx_NEWLINE_xXPatients with evidence of a malignant pleural or pericardial effusion are excludedXx_NEWLINE_xXExclusion at the discretion of the principal investigator (PI) or delegate if participation to the study is deemed too risky (e.g. clinically significant pleural or pericardial effusion or ascites with possibly increased radio-toxicity)Xx_NEWLINE_xXSymptomatic ascites or pleural effusionsXx_NEWLINE_xXIf a pleural effusion is present, the following criteria must be met to exclude malignant involvement (incurable M1a disease):\r\n* When pleural fluid is visible on both the CT scan and on a chest x-ray, a pleuracentesis is required to confirm that the pleural fluid is cytologically negative\r\n* Exudative pleural effusions are excluded, regardless of cytology\r\n* Effusions that are minimal (i.e. not visible under ultrasound guidance) that are too small to safely tap are eligibleXx_NEWLINE_xXHas clinically apparent ascites on physical examination. Note: ascites detectable on imaging studies only ARE allowed.Xx_NEWLINE_xXFor Cohort B: Has ascites and/or clinically significant pleural effusionXx_NEWLINE_xXPatients having:\r\n* Cirrhosis at a level of Child-Pugh B (or worse) or\r\n* Cirrhosis (any degree) and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis; clinically meaningful ascites is defined as ascites from cirrhosis requiring diuretics or paracentesisXx_NEWLINE_xXUncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage at least once monthly.Xx_NEWLINE_xXModerate or severe ascites.Xx_NEWLINE_xXGrade 3-4 ascites or pleural effusion\r\n* Note: The following will NOT be exclusionary: A participant who is clinically stable following treatment for ascites or pleural effusion (including therapeutic thoracentesis or paracentesis)Xx_NEWLINE_xXClinically evident ascites (trace ascites on imaging is acceptable)Xx_NEWLINE_xXMalignant pleural effusionXx_NEWLINE_xXSignificant ascites or pericardial or pleural effusionXx_NEWLINE_xXPatients must have histologically or cytologically-proven new diagnosis of unresectable stage IIIA/IIIB*, non-small cell lung cancer (adenocarcinoma, bronchioloalveolar cell carcinoma, large cell carcinoma, squamous cell carcinoma, or mixed)\r\n* Per the American Joint Committee on Cancer (AJCC) 7th edition, pleural and pericardial are now considered stage M1a disease; when pleural fluid is visible on the computed tomography (CT) scan or on a chest x-ray, a thoracentesis is required to confirm that the pleural fluid is cytologically negative; patients with exudative pleural effusions are excluded, regardless of cytology; patients with effusions that are minimal (i.e. not visible on chest x-ray) that are too small to safely tap are eligible; a small effusion that has positive fludeoxyglucose F 18 (FDG) uptake on positron emission tomography (PET) has to be proven to be malignant per standard of care diagnostic procedures for the patient to be excludedXx_NEWLINE_xXHas symptomatic ascites or pleural effusion.Xx_NEWLINE_xXClinical evidence of ascites by physical examXx_NEWLINE_xXCardiopulmonary dysfunction, symptomatic pleural effusion, pericardial effusion, or ascitesXx_NEWLINE_xXUncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently); participants with indwelling catheters are eligibleXx_NEWLINE_xXHave presence of clinically relevant ascites.Xx_NEWLINE_xXSubjects with ascites or pleural effusion requiring drainage within the last 28 days.Xx_NEWLINE_xXSignificant or symptomatic amount of ascites should be drained prior to first dose of BBI608.Xx_NEWLINE_xXSymptomatic ascites or pleural effusionXx_NEWLINE_xXPleural effusion or ascites that causes respiratory compromise (>= NCI-CTCAE version 4.0 grade 2 dyspnea)Xx_NEWLINE_xXAscites requiring active medical management including paracentesis.Xx_NEWLINE_xXPatients with a pleural effusion that is a transudate, cytologically negative and non-bloody are eligible if the radiation oncologists feel the tumor can still be encompassed within a reasonable field of radiotherapy; if a pleural effusion can be seen on the chest computed tomography (CT) but is too small to tap, the patient is eligibleXx_NEWLINE_xXClinically evident ascites (trace ascites on imaging is acceptable)Xx_NEWLINE_xXUncontrolled pleural, pericardial effusions, or ascites requiring recurrent drainage proceduresXx_NEWLINE_xXHas clinically apparent ascites on physical examinationXx_NEWLINE_xXPresence of a small (or greater size) pericardial effusionXx_NEWLINE_xXPleural effusion or ascites that causes respiratory compromise (? NCI-CTCAE version 4.03 Grade 2 dyspnea).Xx_NEWLINE_xXcirrhosis (any degree) and a history of hepatic encephalopathy or clinically meaningful ascites resulting from cirrhosis. Clinically meaningful ascites is defined as ascites resulting from cirrhosis and requiring ongoing treatment with diuretics and/or paracentesis.Xx_NEWLINE_xXNo history of the following:\r\n* Class III or IV congestive heart failure (CHF)\r\n* Pericardial effusion =< 12 months (grade 3 or 4)\r\n* Pericardial involvement with tumor\r\n* Grade 2 or higher pleural effusion =< 6 monthsXx_NEWLINE_xXAny clinically significant pleural or peritoneal effusion that cannot be drained with standard approaches; an indwelling drainage device placed prior to enrollment is acceptableXx_NEWLINE_xXDiagnosis of histologically or cytologically documented, malignant pleural effusions (primary non-small cell lung carcinoma, mesothelioma, and other histologies), who have free pleural space (partial or total) that permits the intrapleural drug instillation; this includes cytologically negative pleural effusion in conjunction with histologically proven malignancy involving the pleuraXx_NEWLINE_xXSubjects with pleural effusions and/or ascites, due to malignancy, requiring paracentesis every 2 weeks or more frequently.Xx_NEWLINE_xXPatients with only non-measurable lesions other than bone metastasis (e.g. pleural effusion, ascites, etc).Xx_NEWLINE_xXIf pleural fluid is visible on CT scan thoracentesis to exclude malignancy should be obtained. Patients with effusions that are too small to tap are eligible.Xx_NEWLINE_xXGreater than minimal, exudative, or cytologically positive pleural effusionsXx_NEWLINE_xXUncontrolled pleural effusion, pericardial effusion, or ascites (indwelling drainage catheters allowed)Xx_NEWLINE_xXSymptomatic ascites or pleural effusionXx_NEWLINE_xXNo clinical ascites (mild ascites on scans permissible)Xx_NEWLINE_xXAscites requiring interventionXx_NEWLINE_xXHistory of ascites or pleural effusions, unless successfully treated.Xx_NEWLINE_xXSubject has uncontrolled symptomatic ascites.Xx_NEWLINE_xXPatients with symptomatic ascites or pleural effusion; a patient who is clinically stable following treatment for these conditions is eligibleXx_NEWLINE_xXPleural effusions requiring thoracentesis, or ascites requiring paracentesis, within 14 days prior to enrollmentXx_NEWLINE_xXUncontrolled or clinically relevant ascitesXx_NEWLINE_xXHistologically confirmed metastatic ovarian or GI malignancy with malignant ascites amenable for paracentesis; adjudication of malignant ascites can be made on clinical grounds e.g. in the absence of cirrhosis or other non-malignant causes of ascitesXx_NEWLINE_xXPleural effusions requiring thoracentesis within the 14 days prior to randomizationXx_NEWLINE_xXAscites requiring paracentesis within the 14 days prior to randomizationXx_NEWLINE_xXPleural effusion or ascites that causes respiratory compromise (>= NCI-CTCAE version 4.0 grade 2 dyspnea)Xx_NEWLINE_xXPleural effusion or ascites that causes respiratory compromise (>= CTCAE version 4.0 grade 2 dyspnea)Xx_NEWLINE_xXContraindication to any of the required concomitant drugs or supportive treatments or intolerance to hydration due to preexisting pulmonary or cardiac impairment including pleural effusion requiring thoracentesis or ascites requiring paracentesisXx_NEWLINE_xXHave any evidence of hepatic cirrhosis or clinical or radiographic ascitesXx_NEWLINE_xXHave clinically significant and/or malignant pleural effusion (pleural effusions that are not clinically significant are allowed, defined as no more than 25% fluid level of the corresponding hemithorax and stable fluid level [non-progressive] over at least 6 weeks documented radiographically)Xx_NEWLINE_xXPleural effusion or ascites that causes respiratory compromise (>= NCI-CTCAE version 4.0 grade 2 dyspnea)Xx_NEWLINE_xXUncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)Xx_NEWLINE_xXNo clinically significant evidence of pleural effusion or ascitesXx_NEWLINE_xXSubjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to the first day of treatmentXx_NEWLINE_xXNo subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to cycle 1 day 1Xx_NEWLINE_xXUncontrolled tumor-related pain or uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent (once monthly or more frequently) drainage proceduresXx_NEWLINE_xXDocumented extensive disease, defined as any tumor beyond the above limited disease definition, including ipsilateral lung metastases and malignant pleural effusion.Xx_NEWLINE_xXModerate or severe ascitesXx_NEWLINE_xXUncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage proceduresXx_NEWLINE_xXNo moderate-to-severe ascites (subjects with ascites restricted to the perihepatic space or pelvic cavity)Xx_NEWLINE_xXClinical ascitesXx_NEWLINE_xXClinically evident ascites (trace ascites on imaging is acceptable)Xx_NEWLINE_xXPatients with clinically significant pleural or pericardial effusionsXx_NEWLINE_xXPatients with symptomatic effusions on account of pleural, pericardial or peritoneal metastases of melanomaXx_NEWLINE_xXKnown presence of central nervous system metastases, pleural effusions or ascitesXx_NEWLINE_xXSubjects with pleural effusions requiring thoracentesis or ascites requiring paracentesisXx_NEWLINE_xXPresence of symptomatic pleural and/or pericardial effusion not appropriately treatedXx_NEWLINE_xXUncontrolled ascites (defined as not easily controlled with diuretic or paracentesis treatment).Xx_NEWLINE_xXAscites detected by CT, ultrasound (US) or MRI; (trace ascites will not be an exclusion)Xx_NEWLINE_xXPresence of symptomatic pleural and/or pericardial effusion not appropriated treatedXx_NEWLINE_xXContraindication to any of the required concomitant drugs or supportive treatments or intolerance to hydration due to pre-existing pulmonary or cardiac impairment including pleural effusion requiring thoracentesis to ascites requiring paracentesisXx_NEWLINE_xXPatients with a history of malignant pleural effusions are not eligible; pleural effusions considered by the investigator too small for a diagnostic thoracentesis are permissibleXx_NEWLINE_xXPatients with only non-measurable lesions other than bone metastases (e.g., pleural effusion, ascites, etc)Xx_NEWLINE_xXHave any evidence of hepatic cirrhosis or clinical or radiographic ascitesXx_NEWLINE_xXHave clinically significant and/or malignant pleural effusionXx_NEWLINE_xXPatients with a pleural effusion requiring continuous drainageXx_NEWLINE_xXPleural effusion large enough to be detectable on chest x-rayXx_NEWLINE_xXPatients cannot have active ascitesXx_NEWLINE_xXHas symptomatic ascites or pleural effusion. A participant who is clinically stable following treatment for these conditions (including therapeutic thoraco- or paracentesis) is eligible.Xx_NEWLINE_xXSubjects with refractory ascites, defined as ascites needing drainage catheter or therapeutic paracentesis more often than every 4 weeksXx_NEWLINE_xXPatients with a pleural effusion which is a transudate, cytologically negative and non-bloody are eligible if the radiation oncologist feels the tumor can be encompassed within a reasonable field of radiotherapy; patients with exudative, bloody, or cytologically malignant effusions are not eligible; if a pleural effusion can be seen on the chest CT but not on CXR and is too small to tap, the patient will be eligibleXx_NEWLINE_xXFor metastatic solid tumors with documented malignant pleural and/or peritoneal effusions, patients must not be receiving specific therapy for the effusion or have an indwelling drain.Xx_NEWLINE_xXConcurrent medical condition which may increase the risk of toxicity, including:\r\n* Pleural or pericardial effusion of any gradeXx_NEWLINE_xXPatients with any pulmonary infiltrate including those suspected to be of infectious origin. Exception: Patients with a pleural effusion related to the disease under study as confirmed by the investigator are permitted to enter the studyXx_NEWLINE_xXPatients with documented significant pleural or pericardial effusions unless they are thought to be secondary to their leukemiaXx_NEWLINE_xXHas symptomatic ascites or pleural effusionXx_NEWLINE_xXPleural effusion or ascites that causes respiratory compromise (? NCI CTCAE version 4.0 Grade 2 dyspnea).Xx_NEWLINE_xXSubject's with significant fluid retention, including ascites or pleural effusion, may be allowed at the discretion of the principal investigator (PI)Xx_NEWLINE_xXSymptomatic pleural effusion (> CTCAE Grade 1 dyspnea) that is not amenable to drainageXx_NEWLINE_xXRecurrent symptomatic malignant ascites having required at least 2 paracenteses within a 45-day interval prior to baseline paracentesisXx_NEWLINE_xXCompensated cirrhosis defined as a Child-Pugh score of 5 or 6 at Screening • A minimal rim of ascites if detected at imaging is acceptable. Exclude ascites that requires the need to apply diuretic treatment to control ascitesXx_NEWLINE_xXPleural effusion or ascites > 1 literXx_NEWLINE_xXPleural effusion or ascites that causes respiratory compromise (>= NCI-CTCAE version 4.0 grade 2 dyspnea); patients may undergo thoracentesis and paracentesis to improve symptoms prior to enrollmentXx_NEWLINE_xXMalignant pleural, pericardial, or peritoneal effusion if it is the only site of disease activity; i.e., if no other measurable tumor lesions existXx_NEWLINE_xXClinically significant (in the opinion of the Investigator) ascites or pleural effusion requiring chronic medical interventionXx_NEWLINE_xXPatients with clinically evident ascites requiring medical management or paracentesis, or Childs-Pugh score B/C are not eligibleXx_NEWLINE_xXContraindication to any of the required concomitant drugs or supportive treatments or intolerance to hydration due to preexisting pulmonary or cardiac impairment including pleural effusion requiring thoracentesis to ascites requiring paracentesisXx_NEWLINE_xXPrior history of pericarditis or pericardial effusionXx_NEWLINE_xXPatients with a pleural effusion, which is a transudate, cytologically negative and non-bloody, are eligible if the radiation oncologist feels the tumor can be encompassed within a reasonable field of radiotherapyXx_NEWLINE_xXIf a pleural effusion can be seen on the chest CT but not on chest x-ray and is too small to tap, the patient will be eligible; patients who develop a new pleural effusion after thoracotomy or other invasive thoracic procedure will be eligibleXx_NEWLINE_xXClinically significant third-space fluid collections (e.g. ascites or pleural effusion) that cannot be controlled by drainage or other procedures prior to study entryXx_NEWLINE_xXPatients with malignant pleural effusions or significant pericardial effusionsXx_NEWLINE_xXPatients with symptomatic effusions on account of pleural, pericardial or peritoneal metastases of melanomaXx_NEWLINE_xXStage IV cancer according to TNM classification (7th edition - UICC, December 2009; includes tumor with malignant pleural or pericardial effusionXx_NEWLINE_xXPleural effusion large enough to be detectable on chest x-ray (CXR)Xx_NEWLINE_xXPatients require regular ascites/pleural effusion drainageXx_NEWLINE_xXFree flowing pleural effusion requiring management by placement of a pleural catheter; patients with a functional pleural catheter already in place are eligible for the study, as long as there are no clinical concerns of infectionXx_NEWLINE_xXNo free-flowing pleural effusionXx_NEWLINE_xXCardiac ejection fraction >50%, no evidence of pericardial effusion as determined by an ECHO, and no clinically significant pleural effusionXx_NEWLINE_xXClinically significant pleural effusion.Xx_NEWLINE_xXClinically significant pericardial effusion, circumferential pericardial effusion, or any effusion greater than 1.0 cm at any location around the heart.Xx_NEWLINE_xXNo signs of decompensated liver cirrhosis or ascites requiring therapeutic paracentesisXx_NEWLINE_xXUncontrolled ascites requiring weekly large volume paracentesis for 3 consecutive weeks prior to enrollmentXx_NEWLINE_xXUncontrolled pleural effusion, pericardial effusion, or ascitesXx_NEWLINE_xXClinically significant pleural effusionXx_NEWLINE_xXSubjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to randomizationXx_NEWLINE_xXPoorly controlled ascites and/or requirement for therapeutic paracentesis more frequently than once every 3 months.Xx_NEWLINE_xXPatient with pleural effusion, ascites, or pericardial fluid requiring drainage.Xx_NEWLINE_xXPatient has pleural effusion, ascites, or pericardial fluid requiring drainage. Note: Patient who had drain removal ? 14 days prior to planned first dose of study drug and has no sign of worsening is eligible.Xx_NEWLINE_xXPresence of tumor metastases causing significant pleural disease/effusion unilaterally or bilaterally (significant pleural effusion is defined by need for thoracentesis more frequently than once every 21 days)Xx_NEWLINE_xXPresence of ascites that requires paracentesis more frequently than once every 21 days.Xx_NEWLINE_xXMalignant pleural effusion or pleural diseaseXx_NEWLINE_xXPleural effusion requiring repetitive drainage, i.e., an indwelling catheter or 2 thoracenteses with 6 weeks of the first dose of mogamulizumab;Xx_NEWLINE_xXMalignant pleural effusion that is recurrentXx_NEWLINE_xXClinically evident ascitesXx_NEWLINE_xXHistory of recurrent ascites requiring paracentesis within 4 weeks of study day 1.Xx_NEWLINE_xXHave any evidence of hepatic cirrhosis or clinical or radiographic ascitesXx_NEWLINE_xXClinically significant and/or malignant pleural effusionXx_NEWLINE_xXPleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days of first doseXx_NEWLINE_xXPleural effusion, pericardial fluid, or ascites requiring drainage every other week or more frequentlyXx_NEWLINE_xXHistory of medically significant ascites requiring repetitive paracentesisXx_NEWLINE_xXPleural effusion or ascites that causes respiratory compromiseXx_NEWLINE_xXAny cause of dyspnea that is determined by the investigators as readily reversible by other means (e.g. pleural effusion, pulmonary embolism, acute infection, anemia hemoglobin [Hb] < 9.0, etc.)Xx_NEWLINE_xXSubjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to first dose.Xx_NEWLINE_xXSubjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to randomizationXx_NEWLINE_xXPleural effusion or clinically evident (visible or palpable) ascitesXx_NEWLINE_xXPleural effusion or ascites that causes respiratory compromise (>= grade 2 dyspnea)Xx_NEWLINE_xXClinical evidence or portal hypertension (ascites, gastroesophageal varices, or portal vein thrombosis; surgically related ascites does not exclude the patient)Xx_NEWLINE_xXUncontrolled clinical symptoms including pleural effusion, pericardial effusion, or ascites, tumor-related pain, hypercalcemia (or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy)Xx_NEWLINE_xXUncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage proceduresXx_NEWLINE_xXPatients with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to randomization.Xx_NEWLINE_xXHave any evidence of hepatic cirrhosis or clinical or radiographic ascitesXx_NEWLINE_xXHave clinically significant and/or malignant pleural effusionXx_NEWLINE_xXcirrhosis (any degree) and a history of hepatic encephalopathy or ascites resulting from cirrhosis and requiring ongoing treatment with diuretics and/or paracentesisXx_NEWLINE_xXThe participant has clinically significant third-space fluid collections, for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry.Xx_NEWLINE_xXPleural effusions requiring thoracentesis or ascites requiring paracentesisXx_NEWLINE_xXPleural effusions requiring thoracentesis or ascites requiring paracentesisXx_NEWLINE_xXSubjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to randomizationXx_NEWLINE_xXAscites, pleural effusions, or osteoblastic bone metastases as the only site of disease.Xx_NEWLINE_xXPre-existing ascites (abdominal fluid collection) and/or clinically significant pleural effusion ( fluid collection between the lung and chest wall)Xx_NEWLINE_xXPresence of large accumulation of ascites or pleural effusions, which would be a contraindication to the administration of methotrexate for GVHD prophylaxisXx_NEWLINE_xXEvidence of ascites on imaging study, or the use of diuretics for ascitesXx_NEWLINE_xXUncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage proceduresXx_NEWLINE_xXPatients with clinically significant ascites requiring paracentesis on 2 or more occasions within 4 weeks prior to start of study treatmentXx_NEWLINE_xXNo effusion or ascites > 1 L prior to drainageXx_NEWLINE_xXPleural effusion or ascites that causes respiratory compromise (>= grade 2 dyspnea CTCAE)Xx_NEWLINE_xXUncontrolled pleural effusion or ascitesXx_NEWLINE_xXRecent history (within 6 months) of uncontrolled symptomatic ascites or pleural effusions.Xx_NEWLINE_xXAscites requiring paracentesis for symptom improvementXx_NEWLINE_xXPleural effusion requiring thoracentesis within 1 week of study enrollment or scheduled during the study periodXx_NEWLINE_xXSubject has a symptomatic malignant pleural effusion requiring intervention; for an effusion to be defined as malignant, at least one of the following must be true\r\n* There is cytological confirmation of pleural malignancy\r\n* The effusion is an exudate (per Light’s criteria) in the context of histocytologically proven malignancy elsewhere, with no other clear cause for fluid identifiedXx_NEWLINE_xXSubject has sufficient pleural fluid to allow safe insertion of an indwelling tunneled pleural catheter as determined by the principal investigator (PI)Xx_NEWLINE_xXSubject is able to perform home drainage of the pleural effusion or has sufficient resources (family member, caregiver, home health)Xx_NEWLINE_xXAll patients whom do not have malignant pleural effusionsXx_NEWLINE_xXPatients presenting with ascitesXx_NEWLINE_xXPatients with minimal pleural effusion evident on chest X-ray (CXR); minimal pleural effusion visible on chest CT is allowedXx_NEWLINE_xXPresence of ascitesXx_NEWLINE_xXPresence of a symptomatic moderate or large free-flowing pleural effusion on the basis of:\r\n* Chest radiograph: effusion filling >= 1/3 the hemithorax, OR\r\n* Computed tomography (CT)-scan: maximum anteroposterior (AP) depth of the effusion >= 1/3 of the AP dimension on the axial image superior to the hemidiaphragm, including atelectatic lung completely surrounded by effusion, OR\r\n* Ultrasound: effusion spanning at least three rib spaces with depth of 3 cm or greater in at least one interspace, while the patient sits uprightXx_NEWLINE_xXKnown re-expandable lung:\r\n* History of recurrent transudative (by Light’s criteria) pleural effusions of known etiology, AND\r\n* Has undergone multiple prior thoracenteses, without history of significant chest discomfort, AND\r\n* Strong clinical suspicion that the current effusion is uncomplicated and due to the known underlying etiologyXx_NEWLINE_xXPleural effusion is smaller than expected on bedside pre-procedure ultrasoundXx_NEWLINE_xXSigns of third spacing as determined by the treating physician (e.g., pedal edema, pleural effusion, ascites)Xx_NEWLINE_xXMore than 1 biopsy on the same side requiring more than 1 pleural punctureXx_NEWLINE_xXUncontrolled pleural effusion, pericardial effusion, or ascitesXx_NEWLINE_xXModerate or severe ascitesXx_NEWLINE_xXSubject has a history of at least 1 ipsilateral pleural effusion causing dyspnea that responded to thoracentesis where the lung expanded and the dyspnea was improved.Xx_NEWLINE_xXHistory of or current hepatic encephalopathy or clinically meaningful ascites.Xx_NEWLINE_xXPatients with symptomatic pleural effusion requiring placement of an indwelling pleural catheter (IPC) or new placement of an IPC.Xx_NEWLINE_xXPositive effusion cytologyXx_NEWLINE_xXPatients with a pleural effusion that is a transudate, cytologically negative and non-bloody are eligible if the radiation oncologists feel the tumor can still be encompassed within a reasonable field of radiotherapy; patients with exudative, bloody, or cytologically malignant effusions are ineligible; if a pleural effusion can be seen on the chest computed tomography (CT) but not on chest x-ray (CXR) and is too small to tap, the patient will be eligibleXx_NEWLINE_xXPresence of fluid collection (ascites, pleural or pericardial effusion) that interferes with methotrexate clearance or makes methotrexate use contraindicatedXx_NEWLINE_xXAscites absentXx_NEWLINE_xXUncontrolled pleural effusion, pericardial effusion or ascites requiring recurrent drainage proceduresXx_NEWLINE_xXPresence of fluid collection (ascites, pleural or pericardial effusion) that interferes with methotrexate clearance or makes methotrexate use contraindicatedXx_NEWLINE_xXMalignant pleural effusion or pericardial effusionXx_NEWLINE_xXUncontrolled large ascitesXx_NEWLINE_xXPatients with non-measurable non-evaluable lesions such as pleural effusion are not eligible to participateXx_NEWLINE_xXNo clinically significant pleural effusionXx_NEWLINE_xXClinically or radiographically detectable ascites (beyond trace/rim of ascites) or ascites requiring medicationXx_NEWLINE_xXMinimal or non-symptomatic ascitesXx_NEWLINE_xXHas symptomatic ascites or pleural effusionXx_NEWLINE_xXUncontrolled ascites that is not stable with medical management (i.e., on diuretics and salt restriction) as defined by requiring therapeutic paracentesis more than once every 4 weeks.Xx_NEWLINE_xXSubjects with prior history of pericardial effusion or pleural effusion that required thoracentesis are excluded. Subjects with prior history of pericardial or pleural effusion that was clinically manageable and a maintained CMR for ? 1 year on a stable dose of dasatinib are allowed.Xx_NEWLINE_xXUncontrolled ascites requiring weekly large volume paracentesis for 3 consecutive weeks prior to enrollmentXx_NEWLINE_xXUncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)Xx_NEWLINE_xXSignificant pericardial effusion, pleural effusion, or ascitesXx_NEWLINE_xX